Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | NQO1 | P15559 | 2/20 | 0.40 |
| ▸ | POR | P16435 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013425 | 0.85 | ALDH1A1 (0.58) | MAPTKMT2AALDH1A1USP2TSHR | |
| SCHEMBL5986723 | 0.84 | MAPT (0.51) | MAPTSMN1; SMN2ALOX15KMT2AMEN1 | |
| SCHEMBL17876375 | 0.81 | MAPT (0.47) | MAPTSMN1; SMN2ALOX15KMT2AMEN1 | |
| SCHEMBL1500129 | 0.81 | KDM4E (0.68) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL28600756 | 0.79 | MAPT (0.45) | MAPTSMN1; SMN2ALOX15KMT2AMEN1 | |
| SCHEMBL29956322 | 0.79 | PTPN1 (0.61) | MAPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL13555491 | 0.79 | KMT2A (0.56) | MAPTSMN1; SMN2ALOX15KMT2AMEN1 | |
| SCHEMBL13640741 | 0.79 | KDM4E (0.62) | MAPTSMN1; SMN2ALOX15KMT2AMEN1 | |
| SCHEMBL18021729 | 0.78 | ALOX15 (0.49) | MAPTSMN1; SMN2ALOX15KMT2AALDH1A1 | |
| SCHEMBL11508309 | 0.78 | MAOB (0.61) | MAPTSMN1; SMN2ALOX15KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828407-B2 | Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives | LIBRAGEN (FR) | 2017-11-28 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | LIBRAGEN (FR) | 2014-03-27 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110183930-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | LIBRAGEN (FR) | 2011-07-28 | — | — | US | disclosed |
| US-20090233876-A1 | Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives | LIBRAGEN (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | MAPT 3230/4885SMN1; SMN2 4637/4885ALOX15 4151/4885 |
| US-20090233876-A1 | Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives | UGGT1, TYR, LCT | MAPT 1007/4885SMN1; SMN2 4260/4885ALOX15 248/4885 |
| US-20110183930-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | UGGT1, TYR, G6PD | MAPT 1000/4885SMN1; SMN2 4517/4885ALOX15 258/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | MAPT 3250/4885SMN1; SMN2 4634/4885ALOX15 4159/4885 |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | UGGT1, TYR, G6PD | MAPT 1000/4885SMN1; SMN2 4517/4885ALOX15 258/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | MAPT 3250/4885SMN1; SMN2 4634/4885ALOX15 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.